TABLE 1

Summary of Studies Evaluating the Utility of 18F-FDG PET for Therapeutic Response Assessment in NSCLC

NSCLC stageStudyYearNo. of patientsCriteria for response on PETOutcome measureDesignHazard ratio*P
IIIAVansteenkiste et al. (51)19981550% decrease in SUVOverall survivalProspectiveNR0.03
I–IIIMacManus et al. (21)200373CMROverall survivalProspective0.240.0004
IIIB–IVWeber et al. (56)20035720% decrease in SUVOverall survivalProspectiveNR0.005
IIB–IIIHellwig et al. (47)200447SUV < 4Overall survivalProspectiveNR<0.001
IIIAHoekstra et al. (57)200547MRglu < 0.13 μmol/mL/minOverall survivalProspective0.330.0003
IIIPottgen et al. (38)20065050% decrease in SUVTime to extracerebral progressionRetrospectiveNR<0.005
IIIEschmann et al. (53)200770CMR or 80% decrease in SUVOverall survivalProspectiveNR0.005
IB–IVde Geus-Oei et al. (55)200751MRglu > 47%Overall survivalProspectiveNR0.017
35% decrease in SUV0.018
IIIB–IVNahmias et al. (40)200716Decrease in SUV at wk 1–3Overall survivalProspectiveNR0.0016
IIIADooms et al. (48)200830Pathologic response in MLN and >60% decrease in SUV in primary tumorOverall survivalRetrospectiveNR0.002
IIIA–IIIBDecoster et al. (58)200831CMROverall survivalRetrospectiveNR0.004
IB–IIIBTanvetyanon et al. (59)200889CMR or PMROverall survivalProspectiveNRNS

  • ↵* Hazard ratio for patients showing response on PET vs. those showing no response on PET.

  • NR = not reported; MRglu = rate of glucose metabolism; MLN = mediastinal lymph node; NS = not significant.